Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3+7 induction chemotherapy (24 patients). Response rates (P=0.014) and median overall survival (P=0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3+7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (P=0.025), respectively. CLAG-M has encouraging activity in this patient group.
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael V
MV
Jaglal
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA.
Vu H
VH
Duong
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Celeste M
CM
Bello
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Najla H
NH
Al Ali
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Eric
E
Padron
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Hugo F
HF
Fernandez
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Alan F
AF
List
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jeffrey E
JE
Lancet
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: rami.komrokji@moffitt.org.
Rami S
RS
Komrokji
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D001374:Azacitidine / Q000627:therapeutic use*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000592:standards; D017338:Cladribine; D003561:Cytarabine; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects / Q000592:standards; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D017211:Treatment Failure; D055815:Young Adult
D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D017338:Cladribine; D008942:Mitoxantrone; D001374:Azacitidine; D000069585:Filgrastim
Antecedent hematological disorders; Azanucleoside treatment failure; Cladrabine; Secondary AML